Gilead Sciences, Inc. revised earnings guidance for the full year 2021. For the year, the company expected product sales is expected to be in the range of $24,4000 million and $25,000 million compared to previous guidance of $23,700 million and $25,100 million. GAAP projected operating income is expected to be in the range of $9,200 million to $9,900 million compared with previous guidance of $9,000 million to $10,400 million. GAAP projected diluted EPS is expected to be in the range of $4.70 to $5.05 compared with previous guidance of $4.75 to $5.45.